Arcellx (ACLX) Stock Price, News & Analysis

Company Overview

Arcellx, Inc. (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development. Arcellx is advancing lead clinical candidates for relapsed or refractory blood cancers, while exploring applications in solid tumors and autoimmune indications. Manufacturing operations are conducted at the company’s proprietary facility in Malvern, Pennsylvania, with additional process development and scale-up capabilities in the greater Philadelphia region.

Founded in 2018, Arcellx has established collaborations with academic centers and contract research organizations across North America and Europe to support its clinical trial activities. The company is led by an experienced management team with deep expertise in cell therapy research, clinical development and biomanufacturing. Arcellx’s leadership is committed to translating its engineered cell technology into novel treatments that can overcome the limitations of current approaches and address significant unmet medical needs.

Key Stats

• Today's Range: $114.99 to $115.13
• 50-Day Range: $113.76 to $115.10
• 52-Week Range: $47.86 to $115.13
• Volume: 14.67 million shs
• Average Volume: 1.50 million shs
• Market Capitalization: $6.73 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $110.36
• Consensus Rating: Hold

Arcellx Stock Analysis - MarketRank™

Arcellx scored higher than 5% of companies evaluated by MarketBeat, and ranked 880th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Arcellx has received a consensus rating of Hold. The company's average rating score is 2.06, and is based on 1 strong buy rating, no buy ratings, 16 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Arcellx is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Arcellx has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Arcellx are expected to grow in the coming year, from ($2.91) to ($1.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcellx is -28.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcellx is -28.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arcellx has a P/B Ratio of 16.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ACLX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arcellx does not currently pay a dividend.

Dividend Growth

Arcellx does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Arcellx to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arcellx insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.35% of the stock of Arcellx is held by insiders.

Percentage Held by Institutions

96.03% of the stock of Arcellx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 2/26/2026
• Today: 8/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ACLX
• CIK: 1786205
• Web: arcellx.com
• Phone: 240-327-0603
• Fax: N/A
• Employees: 80
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Arcellx: $110.36
• High Price Target: $120.00
• Low Price Target: $82.00
• Potential Upside/Downside: -4.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.06
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$228.93 million
• Net Margins: -1,027.26%
• Pretax Margin: -1,026.94%
• Return on Equity: -55.42%
• Return on Assets: -36.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.44
• Quick Ratio: 4.44

Sales & Book Value

• Annual Sales: $22.29 million
• Price / Sales: 301.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.96 per share
• Price / Book: 16.53

Miscellaneous

• Outstanding Shares: 58,480,000
• Free Float: 53,597,000
• Market Cap: $6.73 billion
• Optionable: Optionable
• Beta: 0.25